FDA declines to approve deramiocel application for Duchenne
The US regulator said on 20 November that the evidence was insufficient for approval. Capricor defends the integrity of its data.

The US Food and Drug Administration announced on 20 November 2026 that it had issued a complete response letter (CRL) for Capricor’s resubmitted deramiocel application. The investigational cell therapy for Duchenne muscular dystrophy did not receive approval.
The agency cites serious data-integrity deficiencies in the HOPE-3 study: unauthorised post-hoc changes to the statistical analysis plan, violations of blinding procedures and protocol violations. According to FDA, the data cannot provide a reliable foundation for establishing effectiveness, and the deficiencies cannot be remedied retrospectively.
Capricor confirmed receipt of the letter but says it stands behind the rigour of its programme and the integrity of its data. The company maintains that HOPE-2 and HOPE-3 met their primary endpoints and that the evidence supports approval. It says it is reviewing the response before determining its next steps.
The amended application concerned upper-limb function, rather than the earlier proposed indication for cardiomyopathy. Deramiocel remains investigational. FDA also said it had issued a separate Regulatory Responsibility Letter, dated 20 November, addressing its inspection observations. According to the agency, Capricor will have an opportunity to respond to that letter.
English translation of the Greek edition · Read in Greek